Sanofi Sees Cemiplimab As Path To Relevance In Immuno-Oncology

The anti-PD-1 candidate is being developed in three cancer indications unserved by checkpoint inhibitors. Along with anti-CD38 isatuximab for multiple myeloma, this represents Sanofi's late push into IO.

Cancer cells

With promising data from a Phase II trial in advanced cutaneous squamous cell carcinoma (CSCC), Sanofi has begun a rolling Biologics License Application (BLA) for cemiplimab, a PD-1 inhibitor that is one of two clinical candidates it is counting on to make a competitive play in immuno-oncology.

Cemiplimab is part of the French pharma's 2015 IO partnership with long-time collaborator Regeneron Pharmaceuticals Inc.[See Deal]...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Immuno-oncology

More from Anticancer